ERBB2 and breast cancer: It was noted that the pyrotinib + chrysin treatment potentiated autophagy in HER2-positive breast cancer cells, whereas the overexpression of miR-16-5p or knockdown of ZBTB16 apparently decreased autophagy, as indicated by simultaneously decreased ratio of LC3-II/LC3-I (Fig. 6b).